Drugs / Reproxalap
Reproxalap
Trials 22 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06826196 | Mar 2025 → Oct 2026 expected | alopecia areata | Aldena Therapeutics | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03709121 | Oct 2018 → Mar 2019 | atopic conjunctivitis | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT03660878 | Sep 2018 → Nov 2019 | conjunctivitis | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT05424549 | Mar → May 2022 | dry eye syndrome | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05102409 | Sep → Oct 2021 | dry eye syndrome | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04971031 | Jun → Sep 2021 | dry eye syndrome | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03916042 | Apr → Nov 2019 | dry eye syndrome | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03404115 | Jan → Jul 2018 | dry eye syndrome | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03162783 | May → Jul 2017 | dry eye syndrome | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03012165 | Dec 2016 → May 2017 | conjunctivitis | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02406209 | Mar 2015 → Apr 2016 | non-infectious anterior uveitis | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04674358 | Nov 2020 → Sep 2021 | dry eye syndrome | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 310 trials | ||||||
| Phase 3 | NCT06493604 | Jun 2024 → Feb 2025 | dry eye syndrome | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT06424444 | Apr → Nov 2024 | dry eye syndrome | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT06389214 | Apr → Jun 2024 | dry eye syndrome | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05234554 | Jan 2022 → Apr 2023 | conjunctivitis | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05062330 | Aug 2021 → Mar 2022 | dry eye syndrome | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT04735393 | Jan 2021 → Oct 2022 | dry eye syndrome | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03879863 | Apr → Oct 2019 | dry eye syndrome | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03445650 | Jul 2018 → Jan 2020 | Sjogren-Larsson syndrome | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03494504 | Mar → Nov 2018 | conjunctivitis | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03131154 | Apr 2017 → Apr 2019 | non-infectious anterior uveitis | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04207736 Comparator | Dec 2019 → Feb 2021 | eye allergy | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 24 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | reproxalap | “This clinical trial assessed the activity of reproxalap, a novel reactive aldehyde species modulator, and estimated clinically relevant thresholds for changes in ocular itching...” PMID 35585427 ↗ May 202220“Randomized Phase 2 Trial of Reproxalap, a Novel Reactive Aldehyde Species Inhibitor, in Patients with Noninfectious Anterior Uveitis: Model for Corticosteroid Replacement.” PMID 32955967 ↗ Sep 2020 “The results suggest that the novel RASP inhibitor reproxalap has the potential to mitigate the signs and symptoms of DED” PMID 33450164 ↗ Jan 2021 |
| Known as | ADX-102 | “ADX-102 1% Topical Dermal Cream (reproxalap)” NCT03445650 ↗ |
| Known as | ALD-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06826196 ↗ |
| Action | Inhibit | “reproxalap, a novel inhibitor of reactive aldehyde species (RASP), for the treatment of ocular inflammation” PMID 32955967 ↗ Sep 2020 |
| Modality | Other / unclassified | “Reproxalap, a novel reactive aldehyde species modulator” PMID 35585427 ↗ May 2022 |
| Route | Topical | “reproxalap 0.5% ophthalmic solution (4 times daily for 6 weeks)” PMID 32955967 ↗ Sep 2020 |